Why Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?Zacks Investment Research • 12/08/22
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal SprayGlobeNewsWire • 12/06/22
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided ApproachGlobeNewsWire • 11/14/22
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma TrailingInvestors Business Daily • 11/09/22
Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/09/22
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus VaccinesGlobeNewsWire • 11/01/22
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022GlobeNewsWire • 10/18/22
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All AgesGlobeNewsWire • 09/26/22
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine CandidateGlobeNewsWire • 09/06/22
Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 08/31/22
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/02/22
Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/01/22